The Nitrogen Is In Same Side Chain As Ester Function Patents (Class 560/38)
-
Publication number: 20120101184Abstract: Presently described are curable compositions comprising a mixture of at least one (e.g. free-radically) polymerizable ionic liquid and at least one other ethylenically unsaturated monomer, oligomer, or polymer. The polymerizable ionic liquid is characterized as having an air to nitrogen curing exotherm ratio of at least 0.70. Also described are articles and methods of making articles from such curable compositions. A monofunctional polymerizable ionic liquid is also described comprising a non-polymerizable substituted imidazolium cationic group and a polymerizable sulfonate anion.Type: ApplicationFiled: August 26, 2010Publication date: April 26, 2012Inventors: Yizhong Wang, Joel D. Oxman, Larry R. Krepski, Peiwang Zhu, Kevin M. Lewandowski, Brian N. Holmes, Richard L. Severance, Joseph D. Rule, Thomas P. Klun
-
Patent number: 8153688Abstract: Esters of 2-phenylalkanenitriles, such as 3-acetoxy-2-(2-chloro-5-(difluoromethoxy)phenyl)propanenitrile and 3-acetoxy-2-(4-chlorophenyl)propanenitrile, and compositions containing such esters, are useful as fungicides at very low concentrations.Type: GrantFiled: December 10, 2007Date of Patent: April 10, 2012Assignee: MCS Laboratories, Inc.Inventor: Donald Wesley Stoutamire
-
Patent number: 8110703Abstract: The invention relates to a retinoid derivative and pharmaceutical composition and use thereof. The compound of the invention is capable of preventing or treating hematological tumors, such as acute leukemia, chronic leukemia, multiple myeloma and lymphoma, solid tumors, such as liver cancer, rectal cancer, mammary cancer and esophagus cancer, and skin disorders, such as psoriasis and acne.Type: GrantFiled: May 31, 2009Date of Patent: February 7, 2012Assignees: Anhui Medical University, Anhui New Star Pharmaceutical Development Co., Ltd.Inventors: Feihu Chen, Jingbo Shi, Yuan Wang, Jun Li, Juan Shen, Jingjing Ruan, Fanrong Wu
-
Publication number: 20120016126Abstract: The present invention relates to an improved method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate. The present invention allows reduction of production costs by reacting low cost reagents, improves yield and is adaptable for mass production.Type: ApplicationFiled: March 30, 2010Publication date: January 19, 2012Applicant: DONG-A PHARMACEUTICAL. CO., LTDInventors: Woo Young Kwak, Heung Jae Kim, Jong Pil Min, Tae Hyun Yoon, Hyun Joo Shim, Moohi Yoo
-
Patent number: 8071783Abstract: A process for preparing a N-phenylisoxazolidin-5-one derivative is provided. The process for preparing the N-phenylisoxazolidin-5-one derivative comprises reacting an ?,?-unsaturated aldehyde with nitrosobenzene in the presence of a N-heterocyclic carbene (NHC) catalyst. A process for preparing an N-alkoxyphenyl protected ?-amino acid ester derivative is further provided. The process for preparing the N-alkoxyphenyl protected ?-amino acid ester derivative comprises reacting an ?,?-unsaturated aldehyde with nitrosobenzene in the presence of a N-heterocyclic carbene (NHC) catalyst to form a N-phenylisoxazolidin-5-one derivative, and then treating the N-phenylisoxazolidin-5-one derivative with an alcohol in the presence of an acid catalyst. A process for preparing an N-alkoxyphenyl protected ?-amino acid ester derivative, comprising treating a N-phenylisoxazolidin-5-one derivative with an alcohol in the presence of an acid catalyst, is also provided.Type: GrantFiled: March 14, 2008Date of Patent: December 6, 2011Assignee: Agency for Science, Technology and ResearchInventors: Yugen Zhang, Jackie Y. Ying, Jayasree Seayad, Pranab K. Patra
-
Publication number: 20110263873Abstract: Provided is an enantioselective, palladium-catalyzed method for the preparation of ?-amino-?,?-unsaturated carboxylic acid derivatives having the formulas II, III, VII and VIII:Type: ApplicationFiled: November 16, 2009Publication date: October 27, 2011Inventors: Murat Acemoglu, Andreas Pfaltz, Claude Schaerer
-
Publication number: 20110263877Abstract: The present invention provides novel cycloalkylmethylamine analogs, and methods of preparing cycloalkylmethylamine analogs. The present invention also provides methods of using cycloalkylmethylamine analogs and compositions of cycloalkylmethylamine analogs. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications.Type: ApplicationFiled: July 5, 2011Publication date: October 27, 2011Applicant: REVIVA PHARMACEUTICALS, INC.Inventors: Laxminarayan Bhat, Seema Rani Bhat
-
Patent number: 7989480Abstract: The present invention relates to a chemical genus of 3-(triaryl)-2-aminopropanol derivative inhibitors of LTA4H (leukotriene A4 hydrolase) useful for the treatment and prevention of inflammatory diseases and disorders.Type: GrantFiled: August 3, 2007Date of Patent: August 2, 2011Assignee: Decode Genetics EHFInventors: Vincent Sandanayaka, Jasbir Singh, David Sullins, Mark E. Gurney
-
Publication number: 20110178316Abstract: Fullerene compounds represented by the formulae Cm[C(R)CON3]n, Cm[C(R)NCO]n, Cm[C(R)NHCORd]n, and Cm[C(R)NH2]n, wherein Cm represents a fullerene moiety having m carbon atoms, m represents an even integer from about 60 to about 200, n represents an integer of about 1 or more, R represents an electron-withdrawing group, and Rd represents an alkoxy or alkylamino group. In addition, processes for preparing these fullerene compounds involving reacting an acyl azide with a fullerene in the presence of a base.Type: ApplicationFiled: July 28, 2009Publication date: July 21, 2011Applicant: Luna Innovations IncorporatedInventor: Jing Zhang
-
Publication number: 20110166342Abstract: A 7-membered heterocyclic compound having the formula (I), or its salt, or a solvate thereof with a chymase inhibitory action and useful for the prevention or treatment of various diseases, in which chymase is involved: a method for producing the same, and a pharmaceutical composition useful for the prevention or treatment of diseases, in which chymase is involved, including the compound of having the formula (I), or its pharmaceutically acceptable salt, or a solvate thereof are provided.Type: ApplicationFiled: January 4, 2011Publication date: July 7, 2011Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tsuyoshi Muto, Taisaku Tanaka, Hiroshi Maruoka, Seiichi Imajo, Yoshiaki Tomimori
-
Publication number: 20110166344Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of Formula I wherein X is N, and A is and compounds used to synthesize the compounds of Formula I.Type: ApplicationFiled: March 8, 2011Publication date: July 7, 2011Applicant: Anadys Pharmaceuticals, Inc.Inventors: Chinh V. Tran, Frank Ruebsam, Douglas E. Murphy, Peter Dragovich, Yuefen Zhou, Lijian Chen, David Kucera, Fritz Blatter, Martin Viertelhaus
-
Publication number: 20110137000Abstract: The invention relates to a process for preparing a polymeric material doped with metal elements, comprising a step of polymerization of at least one monomer comprising at least one ethylenic function, said monomer being complexed with a metal element. Use of the materials obtained by means of this process as catalysts, or luminescent or magnetic materials, or as elements for laser targets.Type: ApplicationFiled: October 7, 2008Publication date: June 9, 2011Inventors: Balland Longeau Alexia, Moreau Louis, Thibonnet Jérôme, Velasquez Emilie
-
Patent number: 7956212Abstract: Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed.Type: GrantFiled: February 2, 2009Date of Patent: June 7, 2011Assignee: XenoPort, Inc.Inventors: Jia-Ning Xiang, Mark A. Gallop, Cindy X. Zhou, Mark Nguyen, Xuedong Dai, Jianhua Li, Kenneth C. Cundy, Nelson L. Jumbe
-
Publication number: 20110130587Abstract: Disclosed is a process for preparing single enantiomers of beta-amino phenylbutyric acid derivatives and pharmaceutically acceptable salts thereof, which affords the desired compounds having special optical configuration. The process comprises a step of chemical synthesis and a step of resolving the optical isomers of beta-amino phenylbutyric acid derivatives with a resolving agent. The resolving step comprises reacting the optical isomers with resolving agents, such as di-para-toluoyl-L-tartaric acid and di-para-toluoyl-D-tartaric acid. The obtained R-beta-amino phenylbutyric acid derivatives (I) have high optical purity, and the total yield of the accumulative resolution of the laevo and the dextro isomer is up to above 70%.Type: ApplicationFiled: April 14, 2009Publication date: June 2, 2011Applicant: Jiangsu Hengrui Medicine Co., Ltd.Inventors: Piaoyang Sun, Yongjiang Chen, Guangliang Yu
-
Publication number: 20110104765Abstract: Provided herein are compositions including diastereomers in substantially diastereomerically pure form and enantiomers in substantially enantiomerically pure form, and processes for preparing them and converting them to metyrosine.Type: ApplicationFiled: October 29, 2010Publication date: May 5, 2011Inventors: Kevin John HALLORAN, Alex COMELY, Zhengming CHEN, Shyam KRISHNAN
-
Publication number: 20110014140Abstract: The invention relates to an improved process for the manufacture of substitute 2-cyanocinnamic esters. This novel economical process provides products in high purity and yields.Type: ApplicationFiled: September 24, 2010Publication date: January 20, 2011Inventors: Jing HUANG, Shuping Jing, Reinhard Karge, Ralf Proplesch
-
Publication number: 20100298559Abstract: There is provided a novel optically active dinickel complex and/or a production method of an optically active amine by an asymmetric Mannich reaction using the dinickel complex as a catalyst. An optically active dinickel complex of Formula (I) or Formula (I?): [where R0, R1, R2, R3, R4, R5, R6, and R7 are each independently a hydrogen atom, a halogen atom, a C1-10 alkyl group or a C1-10 alkoxy group, etc., R2 and R3 together form, together with a benzene ring bonded to them, a naphthalene ring, etc. A novel production method of an optically active amine by an asymmetric Mannich reaction using the dinickel complex as a catalyst.Type: ApplicationFiled: December 10, 2008Publication date: November 25, 2010Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.Inventors: Masakatsu Shibasaki, Shigeki Matsunaga, Zhihua Chen
-
Publication number: 20100261821Abstract: A dispersible carbon nanotube (“CNT”) comprising a CNT backbone and an organic moiety attached to the carbon nanotube backbone and comprising a hydroxyl substituted C6 to C14 aromatic group are described, as well as a CNT-polymer composite and a method of manufacturing the CNT-polymer composite.Type: ApplicationFiled: October 13, 2009Publication date: October 14, 2010Applicants: SAMSUNG ELECTRONICS CO., LTD., KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Jong-jin PARK, Tae-gwan PARK, Yu-han LEE, Kwang-hee LEE
-
Publication number: 20100256367Abstract: The present invention relates to a use of a specific alpha-arylmethoxyacrylate derivative, or its pharmacologically acceptable salt or solvate for preventing and treating metabolic bone diseases.Type: ApplicationFiled: October 14, 2009Publication date: October 7, 2010Applicants: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY, OSCOTEC INC.Inventors: Bum Tae KIM, Yong Ki Min, Yeon Soo Lee, Jung Nyoung Heo, Hyuk Lee, No Kyun Park, Jung-Keun Kim, Se-Won Kim, Seon-Yle Ko
-
Publication number: 20100240617Abstract: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.Type: ApplicationFiled: February 15, 2010Publication date: September 23, 2010Inventors: Kevin R. Lynch, Timothy L. MacDonald, Kevin Guckian, Edward Yin-shiang Lin, Bin Ma
-
Publication number: 20100216878Abstract: The compound 3,3-dimethyl-butyric acid 4-((S)-2-amino-2-methoxycarbonyl-ethyl)-2-(3,3-dimethyl-butyryloxy)-phenyl ester of formula (I) has dopaminergic properties.Type: ApplicationFiled: August 4, 2008Publication date: August 26, 2010Applicant: PROXIMAGEN LTD.Inventor: Christopher Hobbs
-
Publication number: 20100210607Abstract: The present invention relates to derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) having improved anti-inflammatory properties useful in the treatment of inflammation, pain and fever. More particularly, NSAIDs are derivatized with a hydrogen sulfide (H2S) releasing moiety to produce novel anti-inflammatory compounds having reduced side effects.Type: ApplicationFiled: February 11, 2010Publication date: August 19, 2010Applicant: ANTIBE THERAPEUTICS INC.Inventors: JOHN WALLACE, GIUSEPPE CIRINO, VINCENZO SANTAGADA, GIUSEPPE CALIENDO
-
Publication number: 20100204271Abstract: Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (compound A). A crystal of compound A, which shows a particular X-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2?(°) as measured by X-ray powder diffractometry.Type: ApplicationFiled: August 10, 2009Publication date: August 12, 2010Inventors: MOTOHIDE SATOH, TAKAHISA MOTOMURA, TAKASHI MATSUDA, KENTARO KONDO, KOJI ANDO, KOJI MATSUDA, SHUJI MIYAKE, HIDETO UEHARA
-
Patent number: 7772426Abstract: Disclosed is a method for efficiently and highly selectively producing L-2-amino-4-(hydroxymethylphosphinyl)-butanoic acid, which is useful as a herbicide, through a catalytic asymmetric synthesis reaction. Specifically disclosed is a method for producing L-2-amino-4-(hydroxymethylphosphinyl)-butanoic acid which is characterized in that a dehydroamino acid is subjected to an asymmetric hydrogenation by using a rhodium catalyst represented by the formula (2) below and having an optically active cyclic phosphine ligand, and then the resulting product is subjected to hydrolysis: [Rh(R4)(L)]X??(2) [where R4 represents 1,5-cyclooctadien or norbornadien; L represents a substance represented by the following formula (6): (wherein R5 and R8 respectively represent a C1-4 alkyl group; R6 and R7 respectively represent hydrogen atom or hydroxyl group; and Y represents a group selected from groups represented by the following formula (7): (where Me represents methyl group)).].Type: GrantFiled: March 28, 2006Date of Patent: August 10, 2010Assignee: Meiji Seika Kaisha, Ltd.Inventors: Nobuto Minowa, Nozomu Nakanishi, Masaaki Mitomi
-
Publication number: 20100197924Abstract: The present invention relates to synthetic processes for preparation of aminotetralin compounds with kinase inhibitory activity. The invention also provides synthetic intermediates useful in the processes of the invention.Type: ApplicationFiled: December 16, 2009Publication date: August 5, 2010Applicant: Millennium Pharmaceuticals, Inc.Inventors: Alexandra E. Gould, Sean J. Harrison, Hirotake Mizutani, Ming Shen, Thomas E. Smyser, Stephen G. Stroud
-
Patent number: 7759514Abstract: Novel compounds and compositions including those compounds, as well as methods of using and making the compounds are herein described. The compounds are useful in therapeutic applications, including modulation of disease or disease symptoms in a subject (e.g., mammal, human, dog, cat, horse). The compounds are useful as modulators of the mu opioid receptor (MOR) through their binding affinity with that receptor.Type: GrantFiled: May 29, 2007Date of Patent: July 20, 2010Inventors: Bryce A. Harrison, Tiffany Malinky Gierasch, Gregory L. Verdine, Zhangjie Shi
-
Publication number: 20100144606Abstract: The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is N-Cyclohexyl-N3-[2-(3-fluorophenyl)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-?-alaninamide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor) Agonist; an antioxidant; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist; an Histone Deacetylase Inducer; an IKK2 inhibitor; a COX inhibitor; a lipoxygenase inhibitor; a leukotriene receptor antagonist; an MPO inhibitor; a muscarinic antagonist; a p38 inhibitor; a PDE inhibitor; a PPAR? agonist; a protease inhibitor; a Statin; a thromboxane antagonist; a vasodilator; or, an ENAC blocker (Epithelial Sodium-channel blocker); and its use in the treatment of respiratory disease (for example chronic obstructive pulmonary disease (COPD) or asthma); to certain salts of N-Cyclohexyl-N3-[2-(3-fluoType: ApplicationFiled: June 19, 2009Publication date: June 10, 2010Applicant: AstraZeneca ABInventors: Stephen Connolly, Adrian Fisher, Alexander Humphries, Andrew Watts, Katherine Wiley
-
Patent number: 7728167Abstract: The present invention is concerned with the resolution of a mixture of enantiomers of N-protected amino acids by crystallization with enantiomerically pure N-unprotected ?-amino acid derivatives.Type: GrantFiled: December 9, 2004Date of Patent: June 1, 2010Assignee: Degussa AGInventors: Rolf Hoffmann, Michael Kraft
-
Publication number: 20100099886Abstract: A process for preparing a N-phenylisoxazolidin-5-one derivative is provided. The process for preparing the N-phenylisoxazolidin-5-one derivative comprises reacting an ?,?-unsaturated aldehyde with nitrosobenzene in the presence of a N-heterocyclic carbene (NHC) catalyst. A process for preparing an N-alkoxyphenyl protected ?-amino acid ester derivative is further provided. The process for preparing the N-alkoxyphenyl protected ?-amino acid ester derivative comprises reacting an ?,?-unsaturated aldehyde with nitrosobenzene in the presence of a N-heterocyclic carbene (NHC) catalyst to form a N-phenylisoxazolidin-5-one derivative, and then treating the N-phenylisoxazolidin-5-one derivative with an alcohol in the presence of an acid catalyst. A process for preparing an N-alkoxyphenyl protected ?-amino acid ester derivative, comprising treating a N-phenylisoxazolidin-5-one derivative with an alcohol in the presence of an acid catalyst, is also provided.Type: ApplicationFiled: March 14, 2008Publication date: April 22, 2010Inventor: Yugen Zhang
-
Publication number: 20100099907Abstract: Methods of synthesizing a levodopa ester prodrug, salts thereof, and synthetic intermediates thereof are disclosed.Type: ApplicationFiled: October 19, 2009Publication date: April 22, 2010Inventors: Stephen P. Raillard, Adam Mann, Suresh K. Manthati, Randall A. Scheuerman, Tono Estrada, Mark Q. Nguyen, Cindy X. Zhou
-
Publication number: 20100099898Abstract: Disclosed are intermediates and processes for preparing epoxides of the formula: where R and PROT are defined herein. These epoxides are useful as intermediates in the production of biologically active compounds, i.e., in the production of pharmaceutical agents.Type: ApplicationFiled: December 23, 2009Publication date: April 22, 2010Inventor: Michael R. Reeder
-
Publication number: 20100056780Abstract: The present invention relates to novel O-acyloxime derivatives, a preparation method thereof and a pharmaceutical composition comprising the same for prevention and treatment of cardiovascular disease. The O-acyloxime derivatives according to the present invention may valuably be used for prevention and treatment of cardiovascular diseases such as hyperlipidemia, coronary arterial heart disease, atherosclerosis, and myocardial infarction caused by Lp-PLA2, because they have excellent inhibitory effect of Lp-PLA2.Type: ApplicationFiled: November 9, 2009Publication date: March 4, 2010Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Tae-Sook JEONG, Woo-Song LEE, Hyung-Jae JEONG, Yong-Dae PARK, Jong-Min HAN, Hyoung-Chin KIM, Og-Sung MOON, Young-Suk WON
-
Patent number: 7662988Abstract: An ester compound represented by the formula (1): has excellent pest controlling activity and is useful as an active ingredient for a pest controlling agent.Type: GrantFiled: January 16, 2007Date of Patent: February 16, 2010Assignee: Sumitomo Chemical Company, LimitedInventor: Tatsuya Mori
-
Publication number: 20090306384Abstract: The invention provides a process for producing a compound of formula (I), wherein Y is selected from the group consisting of CH3, CH2OH, CH2CH2OH, CH2Br and Br; comprising the steps of: (i) reacting a compound of formula (II), wherein OX represents hydroxy or O?M+, in which M+ is a cation selected from Li+, Na+ and K+, and Y is as defined above; with trans-cinnamaldehyde (III), in the presence of a secondary amine compound; then (ii) treating the product of the preceding step with acid to afford the compound of formula (I). The above process may also be used in the production of tolterodine and fesoterodine, which are useful in the treatment of overactive bladder.Type: ApplicationFiled: May 21, 2007Publication date: December 10, 2009Inventors: Jens Bertil Ahman, Barry Richard Dillon, Alan John Pettman
-
Patent number: 7622504Abstract: Esters of 2-phenylalkanenitriles, such as 3-acetoxy-2-(2-chloro-5-(difluoromethoxy)phenyl)propanenitrile and 3-acetoxy-2-(4-chlorophenyl)propanenitrile, and compositions containing such esters, are useful as fungicides at very low concentrations.Type: GrantFiled: December 20, 2006Date of Patent: November 24, 2009Assignee: MCS Laboratories, Inc.Inventor: Donald Wesley Stoutamire
-
Publication number: 20090270622Abstract: Compounds of the formula I or I?, where the radicals R1 are each, independently of one another, a hydrogen atom or C1-C4-alkyl and R?1, is C1-C4-alkyl; X1 and X2 are each, independently of one another, a sec-phosphino group; R2 is hydrogen, R01R02R03Si— is halogen-, hydroxyl-, C1-C8-alkoxy- or R04R05N-substituted C1-C18-acyl or is R06—X01—C(O)—; R01, R02 and R03 are each, independently of one another, C1-C12-alkyl, unsubstituted or C1-C4-alkyl- or C1-C4-alkoxy-substituted C6-C10-aryl or C7-C12-aralkyl; R04 and R05 are each, independently of one another, hydrogen, C1-C12-alkyl, C3-C8-cycloalkyl, C6-C10-aryl or C7-C12-aralkyl, or R04 and R05 together are trimethylene, tetramethylene, pentamethylene or 3-oxapentylene; R06 is C1-C18-alkyl, unsubstituted or C1-C4-alkyl- or C1-C4-alkoxy-substituted C3-C8-cycloalkyl, C6-C10-aryl or C7-C12-aralkyl; X01 is —O— or —NH—; T is C-bonded C3-C20-heteroarylene; v is 0 or an integer from 1 to 4; X1 in the heteroring of the heteroarylene is bound in the ortho position relativeType: ApplicationFiled: April 19, 2006Publication date: October 29, 2009Inventors: Martin Kesselgruber, Marc Thommen, Mathias Lotz
-
Publication number: 20090247470Abstract: Disclosed are a compound of formula I, stereoisomers, pharmaceutically acceptable salts or hydrates thereof, a pharmaceutical composition comprising the smae, a process for preparing the same and use thereof. The compound may also be used to prepare a medicament to treat viral infections, especially to prepare a medicament to treat hepatitis B virus and human immunodeficiency virus with little toxic side effects.Type: ApplicationFiled: March 27, 2008Publication date: October 1, 2009Applicants: The Key Lab. Of Chemistry for Natural Products of Guizhou Province and Chinese Acad. of Sciences, Tianjin Institute of Pharmaceutical Research, 302 Hospital of PLA, ChinaInventors: Guangyi Liang, Bixue Xu, Changxiao Liu, Zhengming Huang, Peixue Cao, Zegui Cai, Yuming Liu
-
Patent number: 7569720Abstract: This invention relates to newly identified ester-linked gemini surfactant compounds, to the use of such compounds and to their production. The invention also relates to the use of the ester-linked gemini surfactant compounds to facilitate the transfer of polynucleotides into cells.Type: GrantFiled: August 4, 2008Date of Patent: August 4, 2009Assignee: Glaxo Group LimitedInventors: Mariano Javier Castro, Christopher Kitson, Mark Ladlow, Alpesh Patel
-
Publication number: 20090170936Abstract: An ester compound represented by the formula (1): has excellent pest controlling activity and is useful as an active ingredient for a pest controlling agent.Type: ApplicationFiled: January 16, 2007Publication date: July 2, 2009Inventor: Tatsuya Mori
-
Publication number: 20090143465Abstract: An ester compound represented by the formula (I): has excellent pest controlling activity and is useful as an active ingredient for a pest controlling agent.Type: ApplicationFiled: April 27, 2007Publication date: June 4, 2009Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventor: Tatsuya Mori
-
Publication number: 20090105091Abstract: The present invention provides a compound of the general formula (I), wherein X is the connection between the CO-hydrazine and the NR1-oxalic acid or ester group, and uses and synthesis methods. These compounds represent amino acid derivatives, wherein the amine group is turned into an acidic group by the oxalic acid group and the carboxylic acid is turned into an amine functionality by the hydrazine group; as well as peptidomimetics comprising the compound and methods for their synthesis.Type: ApplicationFiled: November 24, 2006Publication date: April 23, 2009Applicant: TECHNISCHE UNIVERSITAT WIENInventors: Ulrich Jordis, Jaywant B. Phopase
-
Patent number: 7514578Abstract: The invention relates to a method for producing enantiomeris form of 2, 3-diaminopropionic acid derivatives of formula (I) by asymetric hydrogenation from compounds of formula (II).Type: GrantFiled: January 10, 2007Date of Patent: April 7, 2009Assignee: sanofi-aventis Deutschland GmbHInventors: Joerg Rieke-Zapp, Guenter Billen
-
Publication number: 20090054679Abstract: The present invention provides a method for producing asymmetrical mono-substituted alkylated compounds of ?-amino acids that are represented by a specific formula, using an aldimine-type Schiff base. In the method of the present invention, the process of alkylating an aldimine-type Schiff base in a medium in the presence of an optically-active quaternary ammonium salt phase-transfer catalyst and an inorganic base is initiated, and subsequently the reaction is quenched at a time earlier than a time for completion of the stoichiometric reaction of the alkylation reaction, so that a mono-substituted alkylated product with high optical purity can be obtained.Type: ApplicationFiled: July 28, 2006Publication date: February 26, 2009Applicant: NAGASE & CO., LTD.Inventors: Keiji Maruoka, Toru Inoue, Jun Matsumoto
-
Publication number: 20090036523Abstract: Described herein are cannabidiol prodrugs, methods of making cannabidiol prodrugs, formulations comprising cannabidiol prodrugs and methods of using cannabidiols. One embodiment described herein relates to the transdermal or topical administration of a cannabidiol prodrug for treating and preventing diseases and/or disorders.Type: ApplicationFiled: July 30, 2008Publication date: February 5, 2009Applicant: AllTranz Inc.Inventors: Audra Lynn Stinchcomb, Miroslaw Jerzy Golinski, Dana Carmel Hammel, Jeffery Lynn Howard, Stan Lee Banks
-
Publication number: 20090018189Abstract: Disclosed herein are compound useful for inhibition of hormone sensitive lipase, pharmaceutical compositions of these compounds, and methods of treatment using these compounds.Type: ApplicationFiled: June 26, 2008Publication date: January 15, 2009Inventors: Jean-Frederic Sauniere, Yat S. Or
-
Publication number: 20090011475Abstract: Disclosed is a method for production of an optically active biphenylalanine compound represented by the formula (2): (wherein, R2 is a protective group of an amino group, and R3 and R4 are each independently a hydrogen atom, etc.) or a salt thereof and an optically active biphenylalanine ester compound represented by the formula (3): (wherein, R1 is an alkyl group, etc.) wherein the method comprises hydrolyzing a biphenylalanine ester compound represented by the formula (1): with a protease produced by a microorganism belonging to Bacillus sp. in the presence of at least one alkali selected from an alkali metal hydroxide and an alkaline earth metal hydroxide.Type: ApplicationFiled: January 15, 2007Publication date: January 8, 2009Inventors: Kiyoshi Sugi, Masahide Tanaka, Yoshihiro Kawada, Daisuke Sasayama
-
Publication number: 20080293678Abstract: The invention describes compositions and kits comprising at least qrie organic nitric oxide enhancing salt of an angiotensin converting enzyme inhibitor, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; Q) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia.Type: ApplicationFiled: March 17, 2006Publication date: November 27, 2008Applicant: NitroMed, Inc.Inventor: David S. Garvey
-
Publication number: 20080171004Abstract: The present invention relates to the use of compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, for the development of UV-A or UV-B protection during use, to corresponding novel compounds and compositions, and to corresponding processes for the preparation of compounds and compositions.Type: ApplicationFiled: March 21, 2006Publication date: July 17, 2008Inventors: Thomas Rudolph, Herwig Buchholz
-
Patent number: 7381745Abstract: The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or both, e.g., in a subject in need thereof, using a compound or formulation of the present invention. The present invention also relates to methods of treating a subject suffering from a chronic or acute disease, malady or condition due at least in part to an abnormality in the activity of an endogenous metabotropic glutamate receptor or a NAALADase enzyme or both, using a compound or formulation of the present invention.Type: GrantFiled: February 25, 2003Date of Patent: June 3, 2008Assignee: Georgetown UniversityInventors: Alan P. Kozikowski, Jarda T. Wroblewski, Fajun Nan
-
Patent number: RE40480Abstract: The invention relates to compounds of formula: wherein R1 is selected from the group consisting of fatty acid acyl groups of 12 to 30 carbon atoms and fatty alcohol groups of 12 to 30 carbon atoms, and wherein R2 is selected from the group consisting of H, fatty acid acyl of 12 to 30 carbon atoms and fatty alcohol groups of 12 to 30 carbon atoms, the same as or different from R1, and the residue of a nutrient, drug, or other bioactive compound, and to the use of these compounds to deliver drugs and other bioactive compounds.Type: GrantFiled: May 1, 1996Date of Patent: September 2, 2008Assignee: Scarista LimitedInventors: Sherri Clarkson, Mehar Manku, Philip Knowles, Peter Redden, Andrea Pitt, Paul Bradley, Paul Wakefield, Austin McMordie, David B. Horrobin